A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation.

Trial Profile

A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2015

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Melphalan; Thalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 10 Dec 2013 Updated results for a median follow-up of 59 months presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 13 Dec 2011 Molecular substudy results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 01 Jul 2011 Planned number of patients changed to 480.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top